Visual and Anatomic Outcomes in nAMD Patients With Subretinal Hemorrhage After Treatment With Faricimab in the TRUCKEE Study

Authors

• Huma Khan
• Hannah Khan
• Aamir Abdul Aziz
• Riya Patel
• Ashkan Abbey
• Robert L. Avery
• Himanshu Banda
• Mark Barakat
• Ramanath Bhandari
• Emmanuel Chang
• Sara Haug
• Nikolas London
• Veeral Sheth
• Jeremy Wolfe, Corewell Health East
• Michael Singer
• Carl J. Danzig
• Arshad M. Khanani

Document Type

Conference Proceeding

Publication Date

6-2026

Publication Title

Investigative Ophthalmology and Visual Science

Abstract

Purpose : Faricimab was FDA-approved for nAMD in Jan 2022. Current agents provide benefit to patients but demonstrate declines in visual acuity as treatments continue. Faricimab is the first bispecific agent inhibiting VEGF-A and Ang-2 pathways for the treatment of nAMD and associated subretinal hemorrhage (SRH). This multi-center, retrospective study evaluates the safety and efficacy of faricimab in real-world nAMD patients with SRH.

Methods : This multi-center retrospective study investigates faricimab treatment for nAMD in both treatment-naïve patients and patients switched to faricimab from other anti-VEGF agents. Data collected includes demographics, treatment history, best-corrected visual acuity (BCVA), central subfield thickness (CST), presence of SRH, and presence of subretinal or intraretinal fluid (SRF or IRF). Snellen visual acuity was converted to the Early Treatment Diabetic Retinopathy Study (ETDRS) scoring. Improvements in visual acuity and CST are evaluated as averages. Improvements in SRH and retinal fluid are evaluated as a proportion of patients. Observed and calculated data is reported. Safety is summarized.

Results : A total of 137 eyes across 113 patients were recorded with SRH at time of first faricimab injection. The average age was 80.5 years and 59.3% of patients were female. Following one faricimab injection, all eyes (n=119) saw a +0.63 letter increase (p=0.92), a CST decrease of -77.17mm (p< 0.0001), and resolution rates for SRH, SRF, and IRF of 34.4%, 33.3%, and 36.4%, respectively. Following three faricimab injections, all eyes (n=96) saw a +1.22 letter increase (p=0.13), a CST decrease of -98.71mm (p< 0.0001), and resolution rates for SRH, SRF, and IRF of 44.8%, 41.7%, and 36.2%, respectively. No adverse events have been reported in these patients.

Conclusions : Faricimab has demonstrated efficacy via anatomic and visual parameters and acceptable safety in previously treated patients with subretinal hemorrhages, a demographic not studied in the trials leading to FDA-approval. Future results will continue to investigate the safety and efficacy of faricimab in real-world patients suffering from nAMD-associated SRH. Latest data will be presented at ARVO 2026.

Volume

67

Issue

7

First Page

506

Comments

Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, May 3-7, 2026, Denver, CO

Last Page

506

Recommended Citation

Khan H, Khan H, Aziz AA, Patel R, Abbey A, Avery RL, et al. [Wolfe J]. Visual and anatomic outcomes in nAMD patients with subretinal hemorrhage after treatment with faricimab in the TRUCKEE study. Invest Ophthalmol Vis Sci. 2026 Jun(67(7):506.